On the metabolism of prostaglandin E1 administered intravenously to human volunteers.

Abstract

We have demonstrated recently the formation of a biologically active metabolite of prostaglandin (PG) E1, 13,14-dihydro-PGE1, during intravenous infusions of PGE1 in patients with peripheral arterial occlusive disease. We have now investigated the levels of the immediate precursor of 13,14-dihydro-PGE1, the biologically inactive 15-keto-13,14-dihydro-PGE1, during intravenous administration of 20 micrograms, 40 micrograms or 80 micrograms PGE1 over a period of 60 min to human volunteers. It was found that levels of 15-keto-13,14-dihydro-PGE1, but not those of PGE1 itself, increased in a dose-dependent manner. Thus, increased formation of 13,14-dihydro-PGE1 from 15-keto-13,14-dihydro-PGE1 with increasing doses of PGE1 can be expected to occur. It remains to be investigated, to which extent formation of small amounts of 13,14-dihydro-PGE1 during intravenous infusion of PGE1 could contribute to the therapeutic effects of PGE1 in patients with peripheral arterial occlusive disease.

• Authors: B A Peskar, W Cawello, W Rogatti, G Rudofsky
• Journal: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society (J Physiol Pharmacol) Vol. 42 Issue 3 Pg. 327-31 (Sep 1991) ISSN: 0867-5910 [Print] Poland
• PMID: 1793892 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 15-keto-13,14-dihydroprostaglandin E2
• Alprostadil
• Dinoprostone

Topics

• Adult
• Alprostadil (blood, pharmacokinetics)
• Dinoprostone (analogs & derivatives, blood)
• Dose-Response Relationship, Drug
• Humans
• Infusions, Intravenous
• Male